142,986 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Bought by Corient Private Wealth LP

Corient Private Wealth LP acquired a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 142,986 shares of the biotechnology company’s stock, valued at approximately $1,430,000.

A number of other large investors have also recently made changes to their positions in the business. Bank of America Corp DE increased its position in shares of BioCryst Pharmaceuticals by 231.6% during the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after acquiring an additional 3,556,208 shares in the last quarter. Pacer Advisors Inc. bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $14,880,000. Wedge Capital Management L L P NC bought a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $3,808,000. ADAR1 Capital Management LLC bought a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $1,330,000. Finally, Perceptive Advisors LLC boosted its stake in BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after purchasing an additional 4,271,504 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $10.09 on Friday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22. The stock has a market cap of $2.58 billion, a PE ratio of -6.73 and a beta of 0.57. The firm’s 50-day simple moving average is $9.75 and its 200 day simple moving average is $9.16.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. During the same quarter last year, the business posted $0.15 EPS. The company’s revenue for the quarter was up 33.6% on a year-over-year basis. As a group, analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on BCRX. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective for the company. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Thursday, August 27th. Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Finally, Wedbush decreased their price target on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.